Seattle Genetics to Host Conference Call and Webcast on December 19, 2019 to Discuss PADCEVTM (enfortumab vedotin-ejfv) Approval

Seattle Genetics, Inc. SGEN will host a conference call and webcast on Thursday, December 19, 2019 to discuss the U.S. Food and Drug Administration approval of PADCEV^TM (enfortumab vedotin-ejfv). Access to the event can be obtained as follows:

LIVE access on Thursday, December 19, 2019
6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time

• Telephone 800-367-2403 (domestic) or +1 334-777-6978 (international); conference ID 7236397
• Webcast available at www.seattlegenetics.com in the Investors section

REPLAY access

• Telephone replay will be available beginning at approximately 9:00 a.m. PT on Thursday, December 19, 2019 through 9:00 a.m. PT on Sunday, December 22, 2019 by calling 888-203-1112 (domestic) or +1 719-457-0820 (international); conference ID 7236397
• Webcast replay will be available on the Seattle Genetics website at www.seattlegenetics.com in the Investors section

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in people's lives. ADCETRIS^® (brentuximab vedotin) and PADCEV^TM (enfortumab vedotin-ejfv) use the company's industry-leading antibody-drug conjugate (ADC) technology designed to bring a powerful medicine directly to cancer cells. ADCETRIS is approved for the treatment of several types of CD30-expressing lymphomas, and PADCEV is approved to treat adults with metastatic urothelial cancer. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer, and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191218005820/en/